Overuse of Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease Compared to Non-IBD Patients on Biologic Therapy.
Sean FineMarc VecchioJoao Filipe Goncalves MonteiroEric VecchioEric J MaoPublished in: Crohn's & colitis 360 (2021)
Patients on biologic therapy unnecessarily undergo surveillance testing for TB. Patients with IBD on biologic therapy are screened annually for TB at a higher rate compared to non-IBD patients. Standardization of care among patients on biologic therapy is necessary to avoid excessive testing in areas with a low incidence of TB.
Keyphrases
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- mycobacterium tuberculosis
- public health
- prognostic factors
- palliative care
- peritoneal dialysis
- stem cells
- mesenchymal stem cells
- risk factors
- weight loss
- cell therapy
- human immunodeficiency virus
- quality improvement
- electronic health record
- health insurance